BLOG

Fierce-Biotech

Pfizer doles out $15M to Cardiff to advance a challenger to Amgen’s KRAS winner Lumakras

Pfizer must have liked what it saw in data presented by Cardiff Oncology for a challenger in KRAS-mutated cancers. The Big Pharma is putting up a $15 million equity investment in the biotech to help bankroll development of the drug.